Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 67Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Sarcoma 6Ovarian Neoplasms 4Brain Neoplasms 4Neoplasms 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Leiomyosarcoma 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HER2-negative Metastatic Breast Cancer 1

Interventions

Docetaxel 11Cisplatin 11Biopsy 7Radiotherapy 6Immunohistochemistry 6Carboplatin 6pembrolizumab 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Cetuximab 5Trastuzumab 4Paclitaxel 4Nivolumab 4Gemcitabine 4Chemotherapy, Adjuvant 4Capecitabine 4Surgical Procedures, Operative 3Specimen Handling 3Radiosurgery 3Ipilimumab 3Goserelin 3Fluorodeoxyglucose F18 3Everolimus 3Erlotinib Hydrochloride 3sacituzumab govitecan 2pyrotinib 2pertuzumab 2bicalutamide 2Taxes 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Salivary Gland Neoplasms × eribulin × Clear all
NCT01613768 2018-09-28

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

University of Washington

Phase 2 Completed
29 enrolled 12 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡